# Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

> **NCT06886360** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 120 (estimated)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** norucholic acid

## Key facts

- **NCT ID:** NCT06886360
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06886360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06886360, "Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06886360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*